Search

Author/Creator Jermann, Philip M.

1. CB‐103: A novel CSL‐NICD inhibitor for the treatment of NOTCH‐driven T‐cell acute lymphoblastic leukemia: A case report of complete clinical response in a patient with relapsed and refractory T‐ALL. Issue 3 (16th June 2022)

Authors:
Medinger, Michael; Junker, Till; Heim, Dominik; Tzankov, Alexandar; Jermann, Philip M.; Bobadilla, Maria; Vigolo, Michele; Lehal, Rajwinder; Vogl, Florian D.; Bauer, Michael; Passweg, Jakob
Journal:
EJHaem
Issue:
Volume 3:Issue 3(2022)
Page Start:
1009
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study. (October 2022)

Authors:
Addeo, Alfredo; Rothschild, Sacha I.; Holer, Lisa; Schneider, Martina; Waibel, Christine; Haefliger, Simon; Mark, Michael; Fernandez, Eugenio; Mach, Nicolas; Mauti, Laetitia; Jermann, Philip M.; Alborelli, Ilaria; Calgua, Byron; Savic-Prince, Spasenija; Joerger, Markus; Früh, Martin
Journal:
Lung cancer
Issue:
Volume 172(2022)
Page Start:
154
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search